Please check your internet connection and try again.
# Urimax (Tamsulosin)
## Overview
Tamsulosin is a selective α1-adrenoceptor antagonist that specifically blocks α1A and α1D receptors in the prostate and bladder neck, leading to smooth muscle relaxation and improved urinary flow.
## Primary Indications
* Management of the signs and symptoms of benign prostatic hyperplasia (BPH).
* Off-label: Medical expulsion therapy (MET) for ureteral stones.
## Adult Dosing
* **BPH:** 0.4 mg orally once daily.
* **Dose Titration:** If no response after 2 to 4 weeks, the dose may be increased to 0.8 mg orally once daily.
* **Max Dose:** 0.8 mg daily.
## Pediatric Dosing
* **Safety/Efficacy:** Not established for pediatric populations. Use is rare and considered off-label for specific urological conditions (e.g., neurogenic bladder) under specialist supervision. Dosing is highly variable and depends on institutional protocols.
## Dose Adjustments
* **Renal Impairment:** No dosage adjustment needed for mild to moderate impairment. Use caution in severe impairment; not studied in patients with CrCl <10 mL/min.
* **Hepatic Impairment:** Not recommended in patients with severe hepatic impairment.
* **CYP3A4/2D6 Inhibitors:** Avoid use with strong inhibitors (e.g., ketoconazole, clarithromycin). If required, monitor closely for hypotension.
## Contraindications
* Hypersensitivity to tamsulosin or any component of the formulation.
## Adverse Effects
* **Common:** Dizziness, headache, abnormal ejaculation (retrograde ejaculation), rhinitis, orthostatic hypotension.
* **Serious:** Severe hypotension/syncope (especially with initial doses or dose increases), priapism, Intraoperative Floppy Iris Syndrome (IFIS) during cataract surgery.
## Key Drug Interactions
* **PDE-5 Inhibitors:** Concomitant use (e.g., sildenafil, tadalafil) increases the risk of symptomatic hypotension.
* **CYP3A4/2D6 Inhibitors:** Increased systemic exposure to tamsulosin.
* **Antihypertensives:** Potential for additive blood pressure lowering; monitor for syncope or dizziness.
## Monitoring
* Monitor blood pressure periodically, especially during initial therapy or after dose escalation.
* Assess for improvement in urinary symptoms (IPSS score).
* Screen for history of cataract surgery and discuss risks of IFIS with ophthalmologist.
## Clinical Pearls
* **Administration:** Take 30 minutes after the same meal each day to ensure consistent bioavailability. Do not crush, chew, or open the capsule.
* **Orthostasis:** Risk is highest shortly after the first dose. Advise patients to sit or lie down if they feel dizzy.
* **Surgery Warning:** Inform patients to notify their ophthalmologist of tamsulosin use prior to cataract surgery.
* **Uncertainty:** Tamsulosin does not reduce prostate size; it only treats symptoms. Long-term efficacy over several years may be limited.
***
**Disclaimer:** This information is for educational purposes only. Drug dosing, contraindications, and interactions can change based on local guidelines and clinical context. Always verify specific therapy with current institutional protocols and the official product monograph.
